Please login to the form below
Ubrelvy
This page shows the latest Ubrelvy news and features for those working in and with pharma, biotech and healthcare.
Biohaven gets FDA approval for migraine drug Nurtec ODT
The new drug’s approval by the FDA follows the agency’s green light for Allergan’s Ubrelvy (ubrogepant) in December. ... That is slightly lower than the $4, 896 annual list price for Ubrelvy, according to ICER.
Latest news
-
Lundbeck gets US approval for migraine drug at heart of Alder takeover
The product category has extended with an orally-active CGRP drug in December when Allergan secured FDA approval for Ubrelvy (ubrogepant), though this isn’t a direct competitor as it is
-
Botox strength bolsters Allergan ahead of AbbVie takeover
Allergan chief executive Brent Saunders said Allergan is entering 2020 with “strong momentum”, helped by approvals such as an FDA green light for new acute migraine therapy Ubrelvy (ubrogepant).
-
Lilly launches migraine med Reyvow at $640 per eight-pill pack
Its closest competitor is Allergan’s Ubrelvy (ubrogepant) – an oral CGRP inhibitor which also has FDA approval in the treatment of acute migraine, with or without aura.
-
Allergan gets FDA nod for first oral CGRP drug for migraine
The US regulator has given a green light to Ubrelvy (ubrogepant) for acute migraine with or without aura, and Ireland-domiciled Allergan says it intends to launch the drug in the ... Atogepant is expected to account for the bulk of Allergan’s sales
-
Allergan’s oral migraine drug closer to US filing
New data keeps Allergan ahead of rival Biohaven
Lundbeck gets US approval for migraine drug at heart of Alder takeover
Botox strength bolsters Allergan ahead of AbbVie takeover
Lilly launches migraine med Reyvow at $640 per eight-pill pack
Allergan gets FDA nod for first oral CGRP drug for migraine
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
To succeed in the acute treatment setting, rimegepant will also have to beat competitors like Reyvow and Ubrelvy, both of which are also oral drugs with very attractive profiles. ... Allergan’s Ubrelvy is the only other oral CGRP antagonist approved
Cortellis Drugs to Watch in 2020 report
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
- Merck & Co's cancer drug Keytruda gaining traction in US
- Tyson Fury takes on his Invisible Opponent in hard hitting ad for suicide prevention charity Campaign Against Living Miserably
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
